Irit Gil-Ad

USPTO Granted Patents = 15 (Patent Applications = 5)

CIPO Patents = 1

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 4.3

ph-index = 6

Forward Citations = 73(Granted Patents)

Location History:

Herzliya, IL (2013 - 2014)
Herzlia, IL (2009 - 2015)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2009-2015

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8975251 - Methods of improving cognitive functions (2015-03-10),

2. 8916610 - Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same (2014-12-23),

3. 8828993 - Psychotropic agents having glutamate NMDA activity (2014-09-09),

4. 8722923 - Conjugates for treating neurodegenerative diseases and disorders (2014-05-13),

5. 8394790 - Psychotropic agents having glutamate NMDA activity (2013-03-12),

6. 8377990 - Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders (2013-02-19),

7. 8377929 - Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same (2013-02-19),

8. 8283381 - Conjugated psychotropic drugs and uses thereof (2012-10-09),

9. 8222296 - Conjugates comprising a GABA- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating CNS disorders (2012-07-17),

10. 8207369 - Conjugates for treating neurodegenerative diseases and disorders (2012-06-26),

11. 8168628 - Conjugated psychotropic drugs and uses thereof (2012-05-01),

12. 7939525 - Conjugated psychotropic drugs and uses thereof (2011-05-10),

13. 7619006 - Conjugated psychotropic drugs and uses thereof (2009-11-17),

14. 7598239 - Conjugated psychotropic drugs and uses thereof (2009-10-06),

15. 7544681 - Conjugated psychotropic drugs and uses thereof (2009-06-09),

Title: Irit Gil-Ad: A Pioneer in Cognitive Function Innovations

Introduction

Irit Gil-Ad is a notable inventor based in Herzlia, Israel, recognized for her groundbreaking contributions to the field of cognitive function improvement. With a remarkable portfolio consisting of 15 patents, her work primarily focuses on innovative methods and formulations that enhance cognitive capabilities and address central nervous system (CNS) disorders.

Latest Patents

Among her latest patents, Irit has developed methods of improving cognitive functions. This innovation includes methods and articles of manufacture for enhancing cognitive function through a conjugate that combines a GABA agonist activity with CNS activity, which are covalently linked. Additionally, her work discloses preventive measures against cognitive impairment and dysfunction. Another significant patent involves an acid addition salt of a nortriptyline-GABA conjugate, alongside a novel crystalline form of a fumaric acid addition salt of the same conjugate. This particular invention highlights processes for preparing these conjugates and their applications in treating CNS disorders and pain management.

Career Highlights

Throughout her career, Irit Gil-Ad has contributed to several reputable institutions, including Ramot at Tel-Aviv University Ltd. and Bar-Ilan University. Her research and innovative spirit have earned her recognition in the academic and scientific communities, establishing her as a figure of influence in the field of cognitive science.

Collaborations

Irit has also collaborated with esteemed colleagues such as Abraham Nudelman and Ada Rephaeli. These partnerships have further enhanced her research capabilities, allowing for more comprehensive studies and innovative solutions in cognitive function enhancement.

Conclusion

Irit Gil-Ad stands out not only for her numerous patents but also for her commitment to advancing our understanding of cognitive functions. Her innovative methods and collaborations exemplify her dedication to improving mental health and cognitive performance, securing her place as a leading inventor in her field.

This text is generated by artificial intelligence and may not be accurate.